Extracorporeal Membrane Oxygenation (ECMO) Machine Market Size, Share, Growth, and Industry Analysis, By Type (Venoarterial (VA),Venovenous (VV),Arteriovenous (AV)), By Application (Respiratory,Cardiac,Extracorporeal Cardiopulmonary Resuscitation (ECPR)), Regional Insights and Forecast to 2035

Extracorporeal Membrane Oxygenation (ECMO) Machine Market Overview

The global Extracorporeal Membrane Oxygenation (ECMO) Machine Market size is projected to grow from USD 224.44 million in 2026 to USD 229.92 million in 2027, reaching USD 272.28 million by 2035, expanding at a CAGR of 2.44% during the forecast period.

The Extracorporeal Membrane Oxygenation (ECMO) Machine Market Market encompasses high-acuity medical systems that provide temporary heart and lung support for patients with severe respiratory or cardiac failure. Globally, there were more than 21,000 ECMO procedures conducted in 2024, with over 600 hospitals providing ECMO therapy. Oxygenators represented 34 percent of all ECMO device components supplied globally. More than 400 new portable ECMO units were deployed in 2024, marking a 28 percent increase in equipment installations compared to 2021. The demand is largely driven by increasing cases of cardiac arrest, severe acute respiratory distress, and sepsis-related complications.

In the United States, more than 300 ECMO centers are operational, accounting for 26 percent of total global ECMO installations. The U.S. conducts between 60 and 70 ECMO procedures per center annually, totaling over 15,000 annual cases nationally. Approximately 45 percent of these are adult cases, 30 percent pediatric, and 25 percent neonatal. The U.S. market remains the largest single regional segment, with a strong focus on portable and dual-mode ECMO systems. Hospitals continue expanding their cardiac rescue and lung failure programs to include ECMO support as part of integrated critical care protocols.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 47 percent of ECMO system installations globally are for venoarterial (VA) modality.
• Major Market Restraint: 28 percent of healthcare institutions cite cost and resource intensity as key barriers to ECMO adoption.
• Emerging Trends: Portable ECMO system usage increased by 28 percent between 2021 and 2023.
• Regional Leadership: North America holds 49 percent of the global ECMO market share in 2024.
• Competitive Landscape: The top three companies—Getinge, Medtronic, and LivaNova—collectively control 35 percent of total market share.
• Market Segmentation: Respiratory applications represent 44 percent of all ECMO use cases globally.
• Recent Development: 90 new ECMO centers were established worldwide between 2023 and 2025.

Extracorporeal Membrane Oxygenation (ECMO) Machine Market Latest Trends

The ECMO market shows rapid transformation driven by miniaturization, portability, and advanced monitoring integration. Between 2021 and 2023, demand for compact ECMO units grew by 28 percent as hospitals prioritized mobility and emergency deployment. Around 35 percent of new ECMO machines shipped in 2024 featured embedded sensors for real-time flow and oxygenation monitoring. Dual-mode ECMO configurations capable of switching between venoarterial (VA) and venovenous (VV) settings now account for 18 percent of all newly installed systems.

Extracorporeal Membrane Oxygenation (ECMO) Machine Market Dynamics

DRIVER

"Rising incidence of cardiac and respiratory failure"

Rising cases of acute cardiac and pulmonary failure have significantly driven ECMO demand. Globally, about 44 percent of ECMO utilization in 2024 was for respiratory failure, while cardiac conditions accounted for 40 percent. During COVID-19 and post-pandemic years, ECMO use in severe acute respiratory distress syndrome (ARDS) increased by over 35 percent across Asia-Pacific and North America. Many hospitals now include ECMO as a standard escalation option after conventional mechanical ventilation. In large tertiary centers, ECMO survival rates average 50 percent, underscoring clinical effectiveness. The expansion of cardiothoracic units and transplant programs has further intensified adoption, especially in hospitals treating complex multi-organ failure cases.

RESTRAINT

"High equipment and operation cost"

High procurement and operational costs remain a primary restraint on market expansion. Establishing a fully functional ECMO center requires advanced infrastructure, extensive training, and consumables that must be replaced after each use. About 28 percent of potential adopters in developing markets delay ECMO installation due to high costs. A complete ECMO setup can cost between 120,000 and 250,000 USD excluding consumables. Skilled personnel requirements add to expenditure, as ECMO programs typically operate with one trained perfusionist per patient. Maintenance of oxygenators and pumps contributes to additional annual costs. Smaller hospitals, particularly in Latin America and Africa, struggle to maintain cost-efficiency due to limited patient volumes.

OPPORTUNITY

"Growth in portable and decentralized ECMO systems"

The growing availability of compact ECMO systems creates new opportunities across emerging healthcare economies. Portable ECMO units weighing under 10 kilograms now represent 15 percent of newly launched devices globally. These smaller systems enable deployment in emergency departments, ambulances, and military medical transport. Dual-mode ECMO capable of operating both VA and VV circuits offers hospitals flexibility to manage diverse clinical conditions. Over 90 new ECMO centers opened worldwide between 2023 and 2025, mostly in middle-income countries adopting portable models. Contract ECMO services and leasing arrangements are emerging trends allowing hospitals to access equipment without upfront investment. The expansion of tele-ECMO and remote supervision has further widened the scope for ECMO support in secondary care hospitals.

CHALLENGE

"Training, staffing, and standardization gaps"

A critical challenge for ECMO program sustainability lies in workforce readiness and protocol standardization. Only 46 percent of ECMO centers worldwide currently operate mobile or retrieval programs due to limited trained teams. Staff shortages, inconsistent clinical protocols, and varied survival rates hinder uniform adoption. On average, small hospitals conduct fewer than ten ECMO runs per year, resulting in skill degradation over time. Survival outcomes can differ by as much as 20 percent between low- and high-volume centers. Additionally, consumable supply gaps—especially oxygenators, which account for 34 percent of total system components—often interrupt operations in developing regions. The need for global standardization in training, accreditation, and safety monitoring remains one of the biggest industry challenges.

Extracorporeal Membrane Oxygenation (ECMO) Machine Market Segmentation

The ECMO market is segmented by type (Venoarterial, Venovenous, and Arteriovenous) and application (Respiratory, Cardiac, and Extracorporeal Cardiopulmonary Resuscitation). Each segment caters to specific clinical requirements, influencing device design, cost structure, and utilization rates. The following sections provide detailed segmentation analysis for each.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Venoarterial (VA): Venoarterial ECMO accounts for 47 percent of total ECMO systems installed globally. It supports both cardiac and respiratory function by circulating oxygenated blood directly into arterial circulation. VA systems are primarily used in cardiogenic shock, cardiac arrest, and post-surgical cardiac failure cases. They are widely adopted in adult intensive care units and transplant centers. The complexity and cost of VA systems are higher compared to other modalities due to advanced pump technology and monitoring requirements.

Venovenous (VV): Venovenous ECMO represents approximately 43 percent of total ECMO usage. It provides respiratory support by reoxygenating venous blood without augmenting cardiac output. VV systems became widely utilized during the COVID-19 pandemic and remain the standard for severe ARDS management. More than 250 centers globally now operate portable VV ECMO setups. Its lower invasiveness and reduced bleeding risk compared to VA mode make it the preferred option for respiratory cases.

Arteriovenous (AV): Arteriovenous ECMO is used less frequently, accounting for 10 percent of total market installations. It operates without an external pump, relying on the patient’s arterial pressure to drive flow. AV systems are primarily used in partial lung support and carbon dioxide removal therapy. They are cost-effective but limited in flow capacity. AV mode is more prevalent in clinical research and low-resource applications, where partial extracorporeal support is sufficient.

BY APPLICATION

Respiratory: Respiratory applications account for 44 percent of all ECMO cases globally. This includes treatment for ARDS, pneumonia, pulmonary embolism, and post-viral respiratory failure. Venovenous mode dominates in this category due to its efficiency in oxygenating blood without additional cardiac support. In major ECMO centers, respiratory runs average between 200 and 300 annually. The increasing global incidence of chronic respiratory disorders has accelerated this segment’s growth, particularly in Asia-Pacific and Europe.

Cardiac: Cardiac applications represent about 40 percent of ECMO usage and involve patients suffering from heart failure, cardiac arrest, and myocardial infarction. Venoarterial systems dominate this segment due to their ability to provide full circulatory support. High-acuity hospitals and transplant centers rely on ECMO for perioperative cardiac care. With cardiovascular diseases accounting for over 30 percent of global deaths annually, ECMO has become a critical life-saving intervention in advanced cardiac programs.

Extracorporeal Cardiopulmonary Resuscitation (ECPR): ECPR represents 15 percent of global ECMO utilization. This emergency application provides circulatory and oxygenation support during cardiac arrest when conventional CPR fails. Around 70 hospitals globally run dedicated ECPR programs, most of them in the United States, Japan, and Germany. ECPR systems are designed for rapid initiation, with simplified circuits and automated controls that can be deployed in less than five minutes. Their expanding adoption in emergency and trauma centers is strengthening ECMO’s presence in acute care markets.

Extracorporeal Membrane Oxygenation (ECMO) Machine Market Regional Outlook

North America leads with 49 percent of global ECMO share, followed by Europe with 27 percent, Asia-Pacific with 21 percent, and the Middle East & Africa with 3 percent. Growth is driven by technology upgrades, clinical adoption, and government healthcare investment in advanced critical care infrastructure.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America remains the largest ECMO machine market with 49 percent global share in 2024. The United States leads the region with more than 300 ECMO centers, collectively performing over 15,000 procedures annually. Canada and Mexico together account for approximately 4 percent of North American ECMO installations. Nearly 60 percent of U.S. tertiary hospitals have ECMO capacity for adults or pediatrics. Portable systems have grown in adoption, representing 35 percent of new installations in 2024. ECMO survival rates in U.S. centers average 52 percent for adults and 65 percent for neonates. Strong reimbursement models, training programs, and integration into transplant and resuscitation units drive regional dominance.

EUROPE

Europe contributes approximately 27 percent of global ECMO utilization, with over 200 hospitals operating full ECMO programs. Germany, France, and the United Kingdom collectively represent 60 percent of European ECMO capacity. Germany alone maintains more than 70 active ECMO centers. European programs emphasize quality control and centralized registries; most countries maintain survival rates between 50 and 60 percent. In 2024, 35 new ECMO centers were launched across Eastern and Southern Europe, expanding access to secondary hospitals. The market is supported by favorable national funding and strong medical device manufacturing from Germany, Sweden, and Italy.

ASIA-PACIFIC

Asia-Pacific accounts for 21 percent of the global ECMO market. China and Japan dominate regional adoption, representing 60 percent of all installations. Japan has more than 100 ECMO-ready hospitals, while China recorded over 6,000 ECMO procedures in 2024. India and South Korea are expanding national ECMO programs through public-private partnerships. Rising cases of respiratory infections, along with improving healthcare spending, continue to drive ECMO deployment. Around 39 new ECMO facilities were opened across Asia-Pacific between 2023 and 2024, including both adult and pediatric programs. Growing emphasis on portable and hybrid ECMO systems is accelerating equipment procurement across regional hospitals.

MIDDLE EAST & AFRICA

The Middle East & Africa region holds 3 percent of the global ECMO share. Saudi Arabia, the United Arab Emirates, and South Africa lead in ECMO capability. The region hosts approximately 25 full-service ECMO centers, with an additional 15 under development as of 2025. Most hospitals rely on imported systems from Europe and Japan. Government investment in cardiac and respiratory emergency infrastructure has accelerated post-2023, with Saudi Arabia alone funding over 10 new ECMO units. In Africa, South Africa remains the primary ECMO hub, performing about 300 runs annually. Limited staff training and high operational costs remain obstacles to broader adoption.

List of Top Extracorporeal Membrane Oxygenation (ECMO) Machine Companies

• MicroPort Scientific Corporation (China)
• XENIOS AG (Germany)
• Medtronic plc (Ireland)
• Terumo Corporation (Japan)
• Getinge Group (Sweden)
• LivaNova PLC (United Kingdom)
• NIPRO Corporation (Japan)
• OriGen Biomedical (United States)
• EUROSETS S.r.l. (Italy)
• ALung Technologies (United States)

Top two companies by market share:

Getinge Group and Medtronic plc lead globally, holding a combined 35 percent market share through extensive product portfolios, modular ECMO units, and global distribution networks.

Investment Analysis and Opportunities

Investments in ECMO technology are focused on miniaturization, modular designs, and telemedicine integration. Between 2023 and 2024, global investment in ECMO device R&D increased by 18 percent. Approximately 15 new compact models were launched in 2024, reducing average device weight by 20 percent. Hospitals in Asia and the Middle East are adopting leasing models that reduce upfront capital costs by up to 30 percent. More than 90 new ECMO programs worldwide during 2023–2025 were partially funded through government or public-private partnerships.

New Product Development

New ECMO machine designs emphasize automation, smart diagnostics, and compact form factors. In 2024, 15 new ECMO products entered the market, most of them featuring integrated flow sensors, self-priming circuits, and lightweight control units. Portable ECMO systems with battery backup capability for 60 minutes are now widely available. Manufacturers are focusing on hybrid ECMO models that can switch between VA and VV configurations, which now represent 18 percent of newly launched devices.

Five Recent Developments

• Ninety new ECMO centers were launched worldwide between 2023 and 2025 to address rising cardiac and respiratory emergencies.
• Portable ECMO systems were deployed in 40 mobile emergency units in the United States and Japan for in-transit life support.
• Getinge introduced a next-generation hybrid VA/VV ECMO platform in 2024 with AI-assisted flow regulation.
• Medtronic expanded its ECMO training and simulation division, certifying more than 1,000 perfusionists globally in 2024.
• Terumo Corporation launched a compact dual-lumen oxygenator in 2025, cutting setup time by 20 percent in intensive care settings.

Report Coverage

The Extracorporeal Membrane Oxygenation (ECMO) Machine Market Market Report provides a detailed analysis of type, application, and regional distribution across 40 countries. It quantifies installations by modality—Venoarterial (47 percent), Venovenous (43 percent), and Arteriovenous (10 percent)—and by application, including respiratory (44 percent), cardiac (40 percent), and ECPR (15 percent). Regional coverage highlights North America’s 49 percent share, Europe’s 27 percent, Asia-Pacific’s 21 percent, and Middle East & Africa’s 3 percent.

Extracorporeal Membrane Oxygenation (ECMO) Machine Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 224.44 Million in 2026
Market Size Value By	USD 272.28 Million by 2035
Growth Rate	CAGR of 2.44% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Venoarterial (VA) Venovenous (VV) Arteriovenous (AV) By Application : Respiratory Cardiac Extracorporeal Cardiopulmonary Resuscitation (ECPR)
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample